Navigation Links
Nektar Therapeutics Announces Third Quarter 2007 Financial Results
Date:11/7/2007

SAN CARLOS, Calif., Nov. 7 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today the company's financial results for the third quarter that ended September 30, 2007.

Revenue totaled $56.3 million in the third quarter of 2007 compared to $58.6 million in the third quarter of 2006. For the nine months ended September 30, 2007, Nektar reported total revenue of $207.3 million compared to $147.8 million in the same period in 2006.

Cash, cash equivalents, and short-term investments were $452.6 million at September 30, 2007 compared to $406.8 million at June 30, 2007.

Nektar reported a net loss of $18.6 million or $0.20 per share in the third quarter of 2007 compared to a net loss of $19.6 million or $0.22 per share in the same period of 2006.

For the nine months ended September 30, 2007, net loss was $71.8 million or $0.78 per share compared to a net loss of $115.9 million or $1.29 per share in the same period in 2006.

"We've made great progress reshaping Nektar this year," said Howard W. Robin, president and chief executive officer of Nektar. "We realigned the company's business and research activities around our PEGylation and pulmonary technology platforms, built a strong executive team, signed a new strategic partnership with Bayer, and are moving two proprietary programs into Phase 2 clinical trials. Finally, for the first time in Nektar's history, we expect almost no operating cash burn for the year."

Mr. Robin will host a conference call today for analysts and investors beginning at 2:00 p.m. Pacific time to discuss the company's performance. This conference call will be available via webcast and can be accessed through a link that is posted on the Investor R
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
2. Prime Therapeutics Receives TIPPS Certification
3. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
4. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... 17, 2014U.S. military personnel who served in Iraq ... traumatic brain injury (TBI) were compared to military ... medical reasons. Differences in measures of overall disability, ... after injury are reported in an article in ... from Mary Ann Liebert, Inc., publishers. The article ...
(Date:4/17/2014)... Colic affects about one in five infants in the ... during the first several months after birth. Research into ... promise; however, the April 1, 2014 issue of the ... on a study, "Probiotics and Infant Colic," concluding that ... for infant colic did not reduce crying or ...
(Date:4/17/2014)... An international team led by researchers at UC Davis ... plays a key role in cell division, also boosts ... the first time the complex has been shown to ... B1/Cdk1 an excellent target to control cellular energy production, ... was published online today in the journal Developmental ...
(Date:4/17/2014)... It,s not uncommon these days to find a colored ribbon ... signify breast cancer. But what color ribbon does one think ... the designated color, for many suffering from the disease, black ... State University study consisting of lung cancer patients, primarily smokers ... shedding more light on the stigma often felt by these ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... Providence Point, Pittsburgh,s new state-of-the-art senior living community ... the original John Kane Hospital, plans to hire over ... Point on Thursday, June 25, from 10 a.m. to ... sponsored by Baptist Homes Society, welcomes applicants for numerous ...
... and Pharmacy Lives are Covered at National, State and ... HealthLeaders-InterStudy, the leading provider of managed care market ... New York state declined between July 2008 and January ... of Managed Market Surveyor-Rx , medical ...
... adversely affect patient care and increase health care costs ... One in four multiple sclerosis (MS) patients are declining ... costs, according to new research conducted by pharmacy benefits ... with an out-of-pocket expense greater than $250 were seven ...
... 1953) is the first winner of the BBVA Foundation ... Frontiers of Knowledge Awards are intended to recognize and ... and their monetary amount a combined purse of ... place them among the world,s foremost award schemes. ...
... based on their facial expressions. A new study, carried out ... at a face for only 100 milliseconds we can ... sadness or fear. Our brains get a first ... for only 100 milliseconds (0.1 seconds). Whether this impression is ...
... to educate, inform, and empower the people of Chicago, SAVE ... live call-in show, "Community Health," on Chicago Access Network Television ... Channel 21. , , Monday,s program will ... who will inform viewers on ways to prevent medication mistakes, ...
Cached Medicine News:Health News:200+ New Jobs Now Available at Providence Point 2Health News:Commercial Medical and Pharmacy Benefit Enrollment Down in New York 2Health News:New Study Finds 1 in 4 Multiple Sclerosis Patients With High Out-of-Pocket Costs Not Filling Prescriptions 2Health News:Joan Massagué wins BBVA Foundation Frontiers of Knowledge Award in Biomedicine 2Health News:Joan Massagué wins BBVA Foundation Frontiers of Knowledge Award in Biomedicine 3Health News:Joan Massagué wins BBVA Foundation Frontiers of Knowledge Award in Biomedicine 4Health News:Brain detects happiness more quickly than sadness 2Health News:The Consumer's Role in Medication Safety -- An Interactive Discussion with a Pharmacist on Live TV 2
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Jan. 27, 2012 Neurodevice firm ... Series B investment round led by ... 2011, and secured non-dilutive funding of ... million Innovation Ohio loan and a ...
... GAITHERSBURG, Md., Jan. 27, 2012 GenVec, Inc. (Nasdaq: ... proprietary technologies to create superior therapeutics and vaccines, today ... License Agreement with Novartis (NYSE: NVS).  Under the extension, ... to support its hearing loss and balance disorders program. ...
Cached Medicine Technology:Neurodevice Firm Checkpoint Surgical Raises $3M 2GenVec Extends Research Collaboration with Global Pharmaceutical Company 2GenVec Extends Research Collaboration with Global Pharmaceutical Company 3
... unique thread design is the ultimate anchor ... to pull out, proven delivery, two sutures ... This provides the orthopedic surgeon a superior ... , ,The TwinFix AB anchor was developed ...
... ConTack Labral Anchor is an L-PLA ... for soft tissue reattachment to bone. ... the bony contour of the glenoid, ... Radial Osteo Compression (ROC) design to ...
... can be used for open or arthroscopic ... a sterile disposable inserter. The unique deployment ... insertion of the anchor into bone. ... allows for the two pre-threaded sutures to ...
... TACIT Threaded Anchor and ... in craniofacial and hand ... secure tissue reattachment and ... The small size facilitates ...
Medicine Products: